

CURIS INC  
Form 8-K  
February 02, 2005

---

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**WASHINGTON, D.C. 20549**

---

**FORM 8-K**

---

**CURRENT REPORT**  
**PURSUANT TO SECTION 13 OR 15(d) OF THE**  
**SECURITIES EXCHANGE ACT OF 1934**

**Date of Report (Date of earliest event reported): February 1, 2005**

---

**Curis, Inc.**

(Exact name of registrant as specified in charter)

---

**Delaware**  
(State or other jurisdiction  
of incorporation)

**000-30347**  
(Commission File Number)

**04-3505116**  
(IRS Employer  
Identification No.)

**61 Moulton Street, Cambridge, MA**  
(Address of principal executive offices)

**02138**  
(Zip Code)

**Registrant's telephone number, including area code: (617) 503-6500**

Edgar Filing: CURIS INC - Form 8-K

**Not Applicable**

(Former name or former address, if changed since last report)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- “ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - “ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - “ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - “ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 8.01. Other Events.**

On February 1, 2005, Curis, Inc. (the "Company") announced that it elected to exercise a co-development option with its collaborative partner, Genentech, Inc., a Delaware corporation ("Genentech"). The Company and Genentech will share development costs in the United States and any future net profits derived from sales in the United States of a therapeutic product candidate for the topical treatment of basal cell carcinoma, a skin cancer. The Company expects that by exercising this co-development and equal cost-sharing option it will incur approximately \$20 million in development expenses through Phase II clinical trials, a portion of which will be booked in the first quarter of 2005.

The full text of the Company's press release regarding the announcement is filed as Exhibit 99.1 to this Current Report on Form 8-K, and is incorporated herein by reference.

**Item 9.01. Financial Statements and Exhibits.**

(c) Exhibits.

The Exhibit to this Current Report on Form 8-K is listed in the Exhibit Index attached hereto.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Curis, Inc.

Date: February 2, 2005

By: /s/ M. Elizabeth Potthoff

---

M. Elizabeth Potthoff

Vice President, General Counsel

**EXHIBIT INDEX**

| <b>Exhibit No.</b> | <b>Description</b>                                   |
|--------------------|------------------------------------------------------|
| 99.1               | Press Release of the Company dated February 1, 2005. |